The Great Debate at ACR Convergence 2020 is: Janus Kinase Inhibitors Should/Should Not Be Used Before Biologics After Methotrexate Failure in RA. No need to hang in suspense. In this resource center, you’ll get the pros and cons, and highlights from other important sessions on rheumatoid arthritis (RA). Plus, you can explore our collection of research reviews, case reports and clinical articles on advances in the diagnosis and management of RA.
Risk of Mortality from SLE By Ansaam Daoud, MD, Loai Dweik, MD, & Omer Pamuk, MD Why was this study done? Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with significant mortality, particularly affecting racial and ethnic minorities. This study aimed to assess national SLE mortality trends over the past two decades, stratified by…
For patients with rheumatoid arthritis (RA), analyzing immune cell diversity in peripheral blood revealed five major immunotype groups, each exhibiting a different response to various biologic or targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs). This is according to a 2024 study published in Annals of the Rheumatic Disease that aimed to stratify the patients based on…
Research from Baker et al. demonstrated a strong association between the presence of metabolic syndrome and lower response rates to advanced therapies in patients with RA.
Maternal Health Insights in Patients with SLE The impact of pregnancy readiness on lupus activity, maternal mental health & pregnancy outcomes By Ceshae Harding, MD, & Megan Clowse, MD, MPH Why was this study done? Patients with systemic lupus erythematosus (SLE) who are pregnant have increased risks of risks maternal and fetal mortality, preeclampsia and…
Sendaydiego et al. asked: Do some DMARDs pose a greater cancer risk than others for patients with RA? Here are insights from the study and its clinical implications.
Over our 25 years as rheumatologists, care has advanced greatly. We each completed our rheumatology training in the late 1990s when both infliximab and etanercept first arrived on the U.S. market, ushering in the era of biologics in rheumatology. Since this time, our greater understanding of the immunologic basis of many rheumatic diseases has translated…
Research & patients reap benefits when patients with rheumatic conditions get involved in patient-facing organizations & in clinical research planning.
Patients with RA not only suffer from functional limitations, but also face increased healthcare costs, primarily due to prescription drug use, says Dr. Yinan Huang.
At the ACR Convergence 2024 Year in Review lecture, experts discussed advancements in disease understanding and treatments, as well as in basic science.
Why this research is relevant to clinicians today & researchers in the future WASHINGTON, D.C.—The ACR Convergence 2024 meeting in Washington, D.C., reflected the continued advancement of science and practical research in the field of rheumatoid arthritis. Highlights this year centered on new RA treatments and new uses of existing treatments; the use of artificial…